GLP-1 marketing disputes and lawsuits: what Novo and Lilly challenged

A GLP-1 marketing dispute usually means Novo Nordisk or Eli Lilly challenging a compounder, clinic, telehealth brand or each other over ad claims, often under the Lanham Act and state false-advertising laws. The cases target “personalized” and “same as” copy, borrowed drug names and dose comparisons. Each case below is an allegation unless a court ruled.

Sources checked on November 2, 2026.

What each side has challenged in court

GLP-1 marketing disputes run on three tracks: false advertising, patent and regulator action. These are the dated events, each tagged as an allegation, a ruling or an agreement.

• Before April 2025 (allegation): Lilly sued Strive Pharmacy in Delaware and Empower Pharmacy in New Jersey, alleging they falsely market compounded tirzepatide as “personalized” when it is mass-produced and has not been clinically tested or approved by the FDA.
• April 2025 (allegation): Lilly filed complaints in the Northern District of California against Mochi Health, Willow Health, Fella Health and Henry Meds. Mochi said its licensed physicians determine the best treatments in compliance with FDA guidance.
• August 5, 2025 (company statement): Novo announced 14 new suits and said courts had issued 44 permanent injunctions in similar cases, including bars on falsely claiming compounded “semaglutide” is FDA-approved, safe or equivalent to Wegovy or Ozempic.
• September 24, 2025 (ruling on a motion to dismiss): In the Henry Meds case, a federal court in Northern California let Lilly’s “personalized” claim proceed and dismissed the “safe and effective” claim for now, with leave to amend.
• February 9, 2026 (allegation, patent): Novo sued Hims & Hers for infringing US Patent 8,129,343 with compounded semaglutide. Its release also says Hims’ promotional campaigns for those products misled consumers.
• March 9, 2026 (agreement): Novo dismissed the patent suit, reserving the right to refile, after Hims agreed to stop advertising compounded GLP-1 products.
• March 26, 2026 (ruling on a motion to dismiss, reported April 6): A federal court in Oakland let Lilly’s false-advertising claims against Fella Health proceed on its “personalized treatment” statements. It found most other challenged statements alleged lack of substantiation, not falsity, and dismissed the corporate-practice-of-medicine claim for lack of standing.
• July 21, 2026 (allegation): Novo sued Lilly in the District of New Jersey under the Lanham Act and state law. It alleges Lilly’s Zepbound and Mounjaro ads compare Lilly’s highest doses with lower doses of Wegovy and Ozempic. Lilly says it stands behind its advertising.
• October 26, 2026 (ruling on a preliminary injunction): The judge denied Novo’s request, finding insufficient evidence that the ads harmed Novo’s sales or goodwill. The judge called the record “very preliminary,” and Novo said the ruling did not decide whether the ads are false.

The FDA’s February 6, 2026 statement is the backdrop. It says “companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA”. It adds that companies cannot state that compounded drugs use the same active ingredient or are clinically proven to produce results. Sibling pages cover the FDA warning-letter rounds and what compounding is.

GLP-1 ad claims named in complaints, by claim type

The table maps each challenged ad element to its source and one copy lesson. The lessons are our reading of the cases as reported.

Three different kinds of GLP-1 marketing dispute

GLP-1 marketing disputes come in three types, and each has a different plaintiff and remedy.

• False advertising and unfair competition (private). A manufacturer sues under the Lanham Act and state law, as Novo and Lilly did in the cases above.
• Patent (private). Novo v. Hims was a patent suit rather than a false-advertising suit. Novo’s release also describes Hims’ promotion.
• Regulator action. The FDA acts through warning letters and public statements, such as the February 6, 2026 list of claims quoted above.

Novo v. Lilly is a dispute between two manufacturers over FDA-approved drugs. It is useful context on comparative claims, but the parties and products differ from a telehealth brand’s ads.

What this means for your ad copy

Before launch, read each line of GLP-1 copy against the claims above. The checks below follow the claims that appear in the filings and rulings.

1. Does any line name or imply another company’s drug or trial?
2. Is “personalized” true to how prescriptions are actually written?
3. Are “generic,” “same active ingredient” and “same as” absent for compounded products?
4. Does anything imply FDA approval, or call a compounded product “safe” or “clinically proven”?
5. Do comparisons use matching doses and current data?
6. Does the landing page say the same thing as the ad?

Affiliate and influencer creative needs the same check. See how to monitor affiliate ads for GLP-1 offers. For platform-side rules on naming drugs, see Ozempic ads and GLP-1 prescription drug ads on Meta.